Phe-Pro-Ala-pNA is a chromogenic substrate of tripeptidyl peptidase. Phe-Pro-Ala-pNA can be used to test tripeptidyl peptidase activity[1].
Trichloroacetic acid is a commonly utilized agent for chemical resurfacing of the face. Trichloroacetic acid is a metabolite of trichloroethylene thought to contribute to its hepatocarcinogenic effects in mice[1][2].
Z-VAD(OMe)-FMK is a cell-permeable and irreversible pan-caspase inhibitor.
TMP269 is a novel and selective class IIa histone deacetylase (HDAC) inhibitor with IC50s of 157 nM, 97 nM, 43 nM and 23 nM for HDAC4, HDAC5, HDAC7 and HDAC9, respectively.
KRAS G12C inhibitor 49 (Compound 3-2M) is an orally active KRAS G12C inhibitor. KRAS G12C inhibitor 49 shows antitumor activity[1].
KRAS G12C inhibitor 26 is a KRAS G12C inhibitor with antitumor effects (WO2021109737)[1].
Cucurbitacin D is an active component in Cucurbita texana, disrupts interactions between Hsp90 and two co-chaperones, Cdc37 and p23. Cucurbitacin D prevents Hsp90 client (Her2, Raf, Cdk6, pAkt) maturation without induction of the heat shock response. Anti-cancer activity[1].
3’-O-(2-Methoxyethyl)-5-methylcytidine is a cytidine analog. Cytidine analogs have a mechanism of inhibiting DNA methyltransferases (such as Zebularine, HY-13420), and have potential anti-metabolic and anti-tumor activities[1].
CD22 ligand-1 (compound 12) is a potent and selective CD22 ligand with KD of 0.335, 30.7 µM for hCD22 and MAG, respectively. CD22 ligand-1 has the potential for the research of B-cell related disease[1].
BAY-876 is the first highly selective GLUT1 inhibitor with IC50 of 0.002 uM. show good metabolic stability in vitro and high oral bioavailability in vivo.
MMAF sodium (Monomethylauristatin F sodium) is an antitubulin agent that inhibit cell division; attenuates its cytotoxic activity compared to MMAE. MMAF sodium is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) to treat several different cancer types.
Myt1-IN-2 is a potent Myt1 inhibitor with an IC50 of <10 nM. Myt1-IN-2 has anticancer effects (WO2021195782A1; compound 28)[1].
CBK289001 (CBK-289001) is a small molecule inhibitor of Tartrate-resistant acid phosphatase (TRAP/ACP5), demonstrates efficacy in a migration assay and IC50 values from 4 to 125 uM.
NT-113 is an irreversible pan-ERBB inhibitor, with IC50s of 0.4, 4.35, 4.18 and 2.08 nM for EGFR, EGFRT790M, ERBB2/HER2 and ERBB4/HER4, respectively, exhibiting anti-glioma activities.
HPPH is a second generation photosensitizer, which acts as a photodynamic therapy (PDT) agent.
Mollugin is a major bioactive component isolated from Rubia cordifolia L.. Mollugin has an anti-cancer therapeutic effect by inhibiting TNF-α-induced NF-κB activation. Mollugin enhances the osteogenic action of BMP-2 via the p38-Smad signaling pathway [1][2].
Rolapitant hydrochloride hydrate (SCH619734 hydrochloride hydrate) is a potent, selective, long-acting and orally active neurokinin 1 (NK1) receptor antagonist with a Ki of 0.66 nM. Rolapitant hydrochloride hydrate does not interact with CYP3A4. Rolapitant hydrochloride hydrate shows potent anti-emetic activity in a ferret emesis model[1][2].
DBCO-NHS ester 3 (Compound 12) is a cleavable linker that is used for making antibody-drug conjugate (ADC). DBCO-NHS ester 3 is a derivative of Dibenzylcyclooctyne (DBCO) obtained by activation of N-hydroxysuccinimide by the carboxylic acid moiety of both methyl-oxanorbornadiene (MeOND) and dibenzoazacyclooctyne (DIBAC)[1][2].
IACS-8803 is a highly potent cyclic dinucleotide STING agonist with robust systemic antitumor efficacy[1].
2’-Fluoro-2’-deoxy-ara-C(Bz)-3’-phosphoramidite is a cytidine analog. Cytidine analogs have a mechanism of inhibiting DNA methyltransferases (such as Zebularine, HY-13420), and have potential anti-metabolic and anti-tumor activities[1].
3’-β-Amino-2’,3’-dideoxy-5’-O-trityl-5-methyl uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1].
Ko 143 is a potent and selective ATP-binding cassette sub-family G member 2 (ABCG2) inhibitor.
Bleomycin A5 hydrochloride is an anti-neoplastic glycoprotein antibiotic. Bleomycin A5 suppresses Drp1‑mediated mitochondrial fission and induces apoptosis in human nasal polyp‑derived fibroblasts[1][2].
Eleutherobin is a potent β-microtubule inhibitor with an IC50 value of 2 μM. Eleutherobin can be isolated from a marine soft coral. Eleutherobin has cytotoxic activity against cancer cells with similar potency to that of Paclitaxel (HY-B0015). Anticancer activity[1][2].
RH1 (NSC 697726) is a potent bioreductive agent with profound anti-cancer activity in vitro and in vivo.
PBRM1-BD2-IN-6 is a potent PBRM1 bromodomain inhibitor with an IC50 value of 0.22 µM. PBRM1-BD2-IN-6 shows antiproliferation activity. PBRM1-BD2-IN-6 has the potential for the research of PBRM1-dependent cancer[1].
STAT3 degrader-1 (compound 295) is a potent STAT3 degrader. STAT3 degrader-1 can be used for researching anticancer[1].
ML228(CID-46742353) is an activator of the Hypoxia Inducible Factor (HIF) pathway; potently activate HIF in vitro as well as its downstream target VEGF.IC50 value: 1 uM (EC50) [1]Target: HIF activatorML228 represents a novel chemotype available to the research community for the study of HIF activation and its therapeutic potential. Not only is the compound substantially different in structure from known HIF activators, ML228 lacks the acidic functional group almost universally present in PHD inhibitors, which may be important for certain disease applications.
ML179 (SR-1309) is a inverse LRH1 (Liver receptor homologue-1) agonist with IC50 of 320 nM. ML179 shows anti-proliferation activity in MDA-MB-231 cells. ML179 has the potential for the research of ER-negative breast cancer[1].
Evobrutinib is an inhibitor of Bruton's tyrosin kinase (Btk) inhibitor extracted from patent US20140162983 example 0174.